Previous 10 | Next 10 |
Precipio (NASDAQ:PRPO) said CFO Carl Iberger will resign, effective Mar. 21 for personal reasons. Matt Gage, who currently serves as director of financial reporting and analysis, has been promoted to interim CFO effective immediately. Gage joined Precipio following its acquisition of Transgen...
NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that Mr. Carl Iberger, Precipio’s CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, ...
Precipio (PRPO) expects revenues of $8.9M in 2021, an increase of $2.8M from prior year; Q4 revenues are seen posting a 25% Y/Y gain to $2.4M. The growth was led by revenue growth in Pathology Diagnostic Testing. Current HemeScreen revenues are driven from its flagship MPN panel; Q4 reve...
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced its unaudited and preliminary results for 2021. The Company anticipates posting revenues of $8.9 million, an increase of $2.8 million from...
Krystal Biotech KRYS +115% says study on VYJUVEKTM for rare skin disease met primary endpoint Petros Pharmaceuticals PTPI +62% 180 Life Sciences, Vaxart gain amid social media buzz; Petros climb over 60% NRx Pharmaceuticals NRXP +48% after Zyesami increased likel...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! I hope you got your rest out over the holiday weekend because we’re starting off Monday with the biggest pre-market stock movers! Source: Eric Urquhart/Shutterstock.com Moving stocks thi...
3 Penny Stocks to Watch Right Now As another week of trading comes to an end, plenty of penny stocks are showing momentum. While some fear both penny stocks and blue chips to have a massive crash following the sizable bullish movement we’ve seen, others say that is unlikely. ...
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from New York State’s Department of Health (NY DOH). Hemescreen can now be...
Precipio, Inc. (PRPO) Q3 2021 Earnings Conference Call November 15, 2021, 05:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Presentation Operator Welcome to the Precipio Shareholder -- Third Quarter 2021 Shareholder Update Conference Call. All participants will ...
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to e...